Effect of aspirin administration on body weight and liver enzymes in male rats

Faraj Hato Johni Al-Bidhani

Department of Anesthesia, Medical Technical Institute, Middle Technical University (MTU), Baghdad, Iraq.

Abstract

The present study was conducted to evaluate the effects of aspirin on body weight and some liver enzyme in rats. The study was done in Veterinary Medicine College, Baghdad University. We used seventy two male rats and randomly divided into three groups (24 in each group). Group-1 was considered as control, Group-2 animals were treated by 40 mg/kg body weight (low-dose) of aspirin and the Group-3 was treated by 100 mg/kg body weight (high-dose) of aspirin. The results showed no significant difference in body weight gain from 0 to 10 days in all groups, while the low and high-dose aspirin treated rats showed decline in bodyweight gain on day 20 and day 30 of aspirin treatment. The liver enzymes, AST and ALT, increased significantly in high-dose of aspirin treated group on day 20 and 30 while the ALP was increased on all time-points in high-dose aspirin treated group.

Introduction

Aspirin (acetylsalicylic acid [ASA]) is a non-steroidal anti-inflammatory drug (NSAID) which is cheap, easily available and has wide applications in medical science such as anti-pyretic, analgesic, anti-inflammatory action and anti-platelet action in coronary artery disease. Aspirin is a safe drug in low doses but can cause adverse effects at high doses. Some of the severe adverse effects of high dose of aspirin are caused by necrosis of blood vessels [1]. Long term usage of aspirin may cause liver and renal toxicity. Aspirin disrupts the formation of prostaglandins in the body by targeting cyclooxygenase [2,3]. Aspirin is involved in the interference of various cancers signaling pathway, sometime used for regulation of tumor suppressor genes, hence long term usage of aspirin in prevention of many types of cancer is envisaged. The absorption of aspirin is rapid after orally administration in the stomach and proximal small intestine by non-ionized passive diffusion at pH of 2-4 [4,5]. About sixty percent of therapeutic concentration of aspirin is bound to plasma proteins. The metabolism of aspirin is via conjugation in the liver to salicylic acid and salicylic acid [6]. Aspirin excretion mainly occurs in the kidney by glomerular filtration processes, the half-life of aspirin ranges from 14-20 minute [7]. The lethal dose of aspirin with acute oral LD50 value is about 0.9 g/kg in rats, the aspirin poisoning in rats from lethal dose range from mild to severe presentation like hepatitis, nephritis and shock [8] and the chronic toxicity of aspirin like delirium and cardiac failure [9]. Chronic toxicity of aspirin in mice occurs at dose of 3 to 20 times the tolerated dose up to a year [10,11].

Materials and Methods

Seventy two male rats (Rattus norvegicus) were used with an average body weight of 200±10 gram. All animals housed in cages measuring 50 X 50 cm at animal house in Veterinary Medicine
College of Baghdad, Iraq. Animals were exposed to similar environment and feeding for climate management and acclimatization two weeks pre-treatment. Rats were fed by protein diet and distilled water. Possibility of animals having any infection was eliminated by giving a course of systemic antibiotics to make sure that they are healthy before the beginning of the study.

The rats were divided to three groups (24 in each group) randomly as following:

**Group-1 (control):** Administration of 0.5 ml of normal saline (0.9% NaCl) by oral gavage per day

**Group-2 (low-dose):** Administration of 0.5 ml of 40 mg/kg body weight of aspirin by oral gavage per day

**Group-3 (high-dose):** Administration of 0.5 ml of 100 mg/kg body weight of aspirin by oral gavage per day

This experiment was carried for thirty days and at different time-points and at the end of experiment we measured the following parameters:

1) The body weight using digital electronic balance

2) Liver enzyme (Alanine transaminase [ALT], Aspartate transaminase [AST] and Alkaline phosphatase [ALP])

**Collection of blood samples**

The blood samples (about 5ml) were collected in a plain tube and allowed to clot at room temperature, and then the sample was centrifuged at 3000 rpm for 15 minute. The serum samples then separated was stored in polyethylene tube at -20°C till the measurement of the liver enzyme.

**Statistical analysis**

We used IBM SPSS version 25.0 (IBM Corporation, Armonk, NY, USA). Descriptive and inferential statistics were used. The significance level was set at p<0.05.

**Results**

**Body weight**

The results showed a significant decline (p<0.05) in body weight gain in low-dose aspirin group and high-dose aspirin group at day 20 and 30 compared to control group as depicted in **Table 1**.

**Table 1: Effect of acetylsalicylic acid (aspirin) on body weight**

| Parameter                        | Treatment                                | Periods of treatment (in days) |
|----------------------------------|------------------------------------------|--------------------------------|
| Body weight (in gm)              | Control (Normal saline)                  | 0     | 10   | 20   | 30   |
|                                  | Low-dose (40 mg/kg body weight aspirin)  | 195.10±1.14a                       | 256.31±0.43a                     | 320.09±1.90a                     | 339.24±1.64a                     |
|                                  | High-dose (100 mg/kg body weight aspirin)| 193.23±2.34a                       | 250.21±1.65a                     | 273.35±2.76b                     | 289.21±2.65d                     |

The superscript small alphabets refer to significant difference at (p≤0.05) among days of treatment

**Table 2: The effect of acetylsalicylic acid (aspirin) on liver enzymes**

| Parameter                        | Treatment                                | Periods of treatment (in days) |
|----------------------------------|------------------------------------------|--------------------------------|
|                                  | Control (Normal saline)                  | 10    | 20   | 30   |
| Aspartate transaminase [AST] (IU/L) | Low-dose (40 mg/kg body weight aspirin)  | 31.32±1.23a                       | 33.02±1.09a                     | 31.75±1.22a                     |
|                                  | High-dose (100 mg/kg body weight aspirin)| 30.09±2.08a                       | 30.43±1.32d                     | 49.32±3.87p                     |
|                                  | Control (Normal saline)                  | 31.05±0.11a                       | 45.61±2.11a                     | 63.02±2.33a                     |
|                                  | Low-dose (40 mg/kg body weight aspirin)  | 11.17±1.87a                       | 13.08±1.76c                     | 11.50±1.05c                     |
|                                  | High-dose (100 mg/kg body weight aspirin)| 10.76±2.07a                       | 21.91±2.05d                     | 31.01±3.64b                     |
|                                  | Control (Normal saline)                  | 14.42±1.21a                       | 36.11±2.07a                     | 48.44±2.55a                     |
|                                  | Low-dose (40 mg/kg body weight aspirin)  | 51.10±1.10b                       | 55.08±4.85d                     | 52.66±3.64c                     |
|                                  | High-dose (100 mg/kg body weight aspirin)| 52.11±3.77d                       | 57.12±2.63d                     | 79.34±2.99d                     |
|                                  | Control (Normal saline)                  | 61.33±4.11a                       | 78.19±3.33a                     | 81.45±2.66a                     |
|                                  | Low-dose (40 mg/kg body weight aspirin)  | 61.33±4.11a                       | 78.19±3.33a                     | 81.45±2.66a                     |
|                                  | High-dose (100 mg/kg body weight aspirin)| 61.33±4.11a                       | 78.19±3.33a                     | 81.45±2.66a                     |

The superscript small alphabets refer to significant difference at (p≤0.05) among days of treatment
Liver enzymes

Baseline data for liver enzymes collected from three groups is shown in Table 2. The result showed significantly increased (p<0.05) in AST enzyme especially in high-dose group on day 20 and day 30 (45.61±2.11, 63.02±2.33 respectively) compared with the control group (33.02±1.09, 31.75±1.22 respectively). Also there appears to be significant increase in AST in low-dose group on day 30 (49.32±3.87) compared to the control group (31.75±1.22).

Table 2 shows significantly increased ALT enzyme concentration on day 20 and 30 in low and high doses of aspirin groups compared with day 10 and also compared with the control group.

Alkaline phosphatase (ALP) enzyme significantly increased in high-dose group on day 10 and 20 (61.33±4.11, 78.19±3.33 respectively), while the results on day 30 treatment of aspirin in both low and high dose group appeared significantly increased (79.34±2.99, 81.45±2.66 respectively) compared to control group (52.66±3.64).

Discussion

Acetylsalicylic acid (aspirin) used as anti-inflammatory drug have side effects as gastrointestinal symptoms, liver damage and renal toxicity. In the present study, we showed that the administration of aspirin with low-dose and high-dose for 10 days, 20 days and 30 days to rats lead to derangement of liver enzymes and interference with body weight gain. Aspirin induced liver toxicity is clear as the metabolism and biotransformation of aspirin occur in liver, sometimes culminating in apoptosis of hepatocytes [12]. The changes at the level of serum proteins may also cause damage to liver. In the present study, elevation of alanin aminotransferase (ALT) found is similar to the study done by Abdel-salam [13]. The findings of present study in which the serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) increased in high-dose aspirin administration for 10 days, 20 days and 30 days shows functional damage to the liver but the mechanism of acetylsalicylic acid causing this damage cannot be elucidated as liver toxicity after aspirin administration need several days to develop the symptoms according to a group of researchers [14]. A study group reported that administration of aspirin with low-dose daily decreases the progression of fibrosis in rat liver [15]. One study advocated that liver toxicity induced by aspirin could be an outcome of idiosyncratic metabolic reaction because aberrant metabolism of the drug may cause aggregation of toxic metabolites in hepatocytes thereby binding to cell proteins leading to abnormalities [16]. Administration of aspirin upto doses of 40 mg/kg in rats lead to decrease body weight gain while doses more than 100 mg/kg lead to mild sinusoidal congestion suggesting that aspirin at higher doses is hepatotoxic as evident by elevation in serum alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase.

Conclusion

In conclusion, the results of study shows the chronic administration of aspirin lead to hepatotoxic in rats, large-scale studies maybe needed to know the chemo preventive effect of aspirin on liver toxic development, liver toxic associated to aspirin is an common adverse effect it is important to be vigilant to the hepatotoxicity, aspirin causes blocking certain chemical processes in the body that cause inflammation, taking of aspirin with high dose for 30 days can lead to hepatic problems and problems in the histological architecture at the liver which is recommended that aspirin should not be taken at extended duration than normally, the antioxidant supplementation may be beneficial to the people who using aspirin for long periods.

Declarations

Ethical consideration

This study received ethical approval and consent from the Ethical Committee, Medical Technical Institute, Middle Technical University, Iraq.

Funding

This study was self funded.

Disclosure of relationships and activities

Authors have declared that no conflicting interests exist.

Acknowledgements

The authors would like to thank all who supported the study.

References

1. Wanless IR, Liu JJ, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). Hepatology. 1995 May;21(5):1232-7. PMID: 7737628.
2. Turner G, Collins E. Fetal effects of regular salicylate ingestion in pregnancy. Lancet. 1975 Aug 23;2(7930):338-9. doi: 10.1016/s0140-6736(75)92779-8. PMID: 51143.
3. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ. 2000 Jun 17;320(7250):1642-6. doi: 10.1136/bmj.320.7250.1642. PMID: 10856067; PMCID: PMC27410.
4. Kawar ME, Reham EM. Salicylate hepato-toxicity in a patient with systemic lupus erythematosus: A case report. JRMS. 2010; 17:43-45.
5. Ahmed SK. Hepatic and renal biochemical responses to the toxicological interaction between acetylsalicylic acid and diazinon in albino rats. J Egypt Soc Toxicol. 2006 Jul; 35:1-6.

6. Yasmeen T, Yasmin F, Qureshi GS. To evaluate the role of diclofenac sodium on renal parenchyma of young albino rats. Pak J Pharm Sci. 2008 Apr;21(2):98-102. PMID: 18390437.

7. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998 Feb 1;58(3):409-12. PMID: 9458081.

8. Longnecker DS, Curphey TJ. Adenocarcinoma of the pancreas in azaserine-treated rats. Cancer Res. 1975 Aug;35(8):2249-58. PMID: 1097106.

9. Daly JM, Tee LB, Oates PS, Morgan RG, Yeoh GC. Glutathione S-transferase (mu class) as an early marker of azaserine-induced foci in the rat pancreas. Carcinogenesis. 1991 Jul;12(7):1237-40. doi: 10.1093/carcin/12.7.1237. PMID: 1712677.

10. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005 Dec 1;353(22):2373-83. doi: 10.1056/NEJMra052717. PMID: 16319386.

11. Rau Y, Farzana Y, Ghulam S. To evaluate the role of Aspirin (a NSAID) on renal parenchyma of young albino rats. Pak J Pharm Sci. 1989; 21:98-102.

12. Sangeetha B, Krishnakumari S. Tephrosia Purpurea (Linn.) Pers: A folk medicinal plant ameliorates carbon tetrachloride induced hepatic damage in rats. Int J Pharm Bio Sci. 2010 Apr-Jun; 1(2).

13. Abdel-Salam OM, Baioumy AR, Ameen A, Hassan NS. A study of unfractonated and low molecular weight heparins in a model of cholestatic liver injury in the rat. Pharmacol Res. 2005 Jan;51(1):59-67. doi: 10.1016/j.phrs.2004.04.009. PMID: 15519536.

14. Poulol-Robert A, Boëlle PY, Conti F, Durand F, Duvoux C, Wendum D, Paradis F, Mackiewicz V, Chazouillères O, Corpechot C, Poupon R. Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation. Clin Res Hepatol Gastroenterol. 2014 Oct;38(5):570-6. doi: 10.1016/j.clinre.2014.07.004. Epub 2014 Aug 15. PMID: 25130796.

15. Aprioku JS, Nwidu LL, Amadi CN. Evaluation of toxicological profile of ibuprofen in wistar albino rats. Am J Biomed Sci. 2014 Jan; 6(1):32-40. doi: 10.5099/aj140100032

16. Temple AR. Acute and chronic effects of aspirin toxicity and their treatment. Arch Intern Med. 1981 Feb 23;141(3 Spec No):364-9. doi: 10.1001/archinte.141.3.364. PMID: 7469627.